Abstracts tagged "Disease Activity"

Abstract Number: 694 • 2017 ACR/ARHP Annual Meeting
Serum Wisteria Floribunda Agglutinin-Positive Mac-2-Binding Protein Can Reflect Systemic Lupus Erythematosus Activity
Sung Soo Ahn¹, Younhee Park², Seung Min Jung¹, Jason Jungsik Song¹, Yong-Beom Park¹ and Sang-Won Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ²Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
Abstract Background/Purpose : Serum Mac-2-binding protein (M2BP) is elevated in various chronic inflammatory diseases. Recently, the Wisteria floribunda agglutinin positive-M2BP (WFA+-M2BP) immunoassay has shown promise…
Abstract Number: 1238 • 2017 ACR/ARHP Annual Meeting
The Development of the Lupus Foundation of America—Rapid Evaluation of Activity in Lupus (LFA-REAL™) Patient-Reported Outcome (PRO) to Evaluate Lupus Disease Activity
Anca Askanase¹, Samantha Nguyen², Miya Okado², Nancy Leidy³ and Joan T. Merrill⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ³Evidera, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The LFA REALTM is designed as two complimentary disease activity measures in order to integrate clinician and patient input. The current report updates progress…
Abstract Number: 1549 • 2017 ACR/ARHP Annual Meeting
A Non-Medical Switch from Originator Infliximab to Biosimilar CT-P13 in 36 Patients with Ankylosing Spondylitis: 6 – Months Clinical Outcomes from the Czech Biologic Registry Attra
Šárka Forejtová¹, Jakub Zavada¹, Lenka Szczukova², Katerina Jarosova¹, Tom Philipp³ and Karel Pavelka⁴, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Brno, Czech Republic, ³Department of Rheumatology and Physiotherapy, Thomayer Hospital, Prague, Praha 4, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: A non-medical switch from originator (INX, Remicade) to biosimilar infliximab (CT-P13, Remsima) was conducted in 36 patients with ankylosing spondylitis (AS) in one clinical…
Abstract Number: 1847 • 2017 ACR/ARHP Annual Meeting
The IgG4:IgG RNA Ratio in Peripheral Blood Perfectly Differentiates Active Disease from Remission in Granulomatosis with Polyangiitis. a New Disease Activity Marker?
Aram Al-Soudi^1,2,3, Marieke E. Doorenspleet⁴, Rebecca Esveldt⁵, Lot Burgemeister⁵, Liesbeth Hak⁵, Sander W. Tas⁶, Ronald F van Vollenhoven⁷, Paul L. Klarenbeek^5,8 and Niek de Vries^5,9, ¹Dept of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands, ²Dept of Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Dept of Genome Analysis, Academic Medical Center, Amsterdam, Netherlands, ⁴ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁷Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁸Dept. of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁹Laboratory of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is characterized by vasculitis in lungs, kidneys and the ear, nose and throat region. Regular monitoring and treatment adjustments are…
Abstract Number: 2346 • 2017 ACR/ARHP Annual Meeting
Chemokine Ligand 9 (CXCL9) [Monokine Induced By Gamma Interferon (MIG)] As a Predictor of Active Disease Status in Localized Scleroderma
Kathryn S. Torok¹, Qi Mi², Emily Mirizio³, Kaila Schollaert-Fitch¹, Mark Fritzler⁴ and Marvin J. Fritzler⁵, ¹Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ²Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA, ³Pediatric Rhuematology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Eve Technologies, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Localized scleroderma (LS) is a fibrotic autoimmune disease of the skin and underlying tissues which can lead to disfiguring sequlea, especially in childhood-onset. Untreated…
Abstract Number: 2550 • 2017 ACR/ARHP Annual Meeting
A New and Simpler Tool for Global Psoriatic Arthritis Assessment: Simplified Composite Psoriatic Disease Activity Index (sCPDAI)
Maria Laura Acosta Felquer¹, Musaab Elmamoun², Agnes Szentpetery^3,4, Phil Gallagher⁵, Oliver FitzGerald⁶ and Enrique R. Soriano⁷, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ³Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Bone & Joint Unit, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁶St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ⁷Rheumatology Unit, Internal Mecine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The heterogeneity of psoriatic arthritis ( PsA) that includes a possible combination of axial disease, peripheral arthritis, enthesitis, dactylitis, skin and nail involvement, makes…
Abstract Number: 2917 • 2017 ACR/ARHP Annual Meeting
Neutrophil Activation in Rheumatoid Arthritis – Potential Biomarkers of Disease Activity and Severity
Mary Bach¹, Daniel Moon², Marcel Bach², Marcus Bach² and Christian Lood³, ¹VA Puget Sound Health Care System, Seattle, WA, ²University of Washington, Seattle, WA, ³Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Neutrophil activation is associated with inflammation and autoimmunity, including rheumatoid arthritis (RA), where neutrophil infiltration to joints participates in tissue destruction and development of…
Abstract Number: 163 • 2017 ACR/ARHP Annual Meeting
Fibromyalgia Patients Identify More Causes of Disease Flare Ups Than RA Patients
Robert S. Katz¹, Lauren Kwan² and Jessica L. Polyak², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates S.C., Chicago, IL
Background/Purpose: We compared patients with the Fibromyalgia Syndrome (FMS) and Rheumatoid Arthritis (RA) patients with respect to stresses that the patients believe may have caused…
Abstract Number: 699 • 2017 ACR/ARHP Annual Meeting
Impact of Anti-RBP Antibodies on Disease Activity and Quality-of-Life in Immunosuppressant Naive Systemic Lupus Erythematosus
Rene Bermea¹, Tammy Utset² and Kichul Ko³, ¹Medicine, University of Chicago, Chicago, IL, ²Medicine, Section of Rheumatology, University of Chicago, Chicago, IL, ³Medicine, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL
Background/Purpose: There is a lack of phenotypic data on SLE patients who have never been on immunosuppressive therapy. Anti-RNA binding protein (anti-RBP) antibodies (anti-Smith, anti-RNP,…
Abstract Number: 1241 • 2017 ACR/ARHP Annual Meeting
Understanding Differences in Patient Definitions of RA Flares Using Omeract Core Domains
Gabriela L. Maica¹, Michelle Frits², Christine Iannaccone³, Taysir G. Mahmoud⁴, Clifton O. Bingham III⁵, Vivian P. Bykerk⁶, Michael Weinblatt⁷ and Nancy A. Shadick⁸, ¹Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶2-005, Mt Sinai Hospital, Toronto, ON, Canada, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Flare is an important, distinct feature of RA, often rendering patients immobile and contributing to a poor quality of life. Recently, there has been…
Abstract Number: 1552 • 2017 ACR/ARHP Annual Meeting
Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Yujin Park⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: There are limited data regarding persistency of TNF inhibitor (TNFi) therapies in patients with ankylosing spondylitis (AS) treated in real-world clinical practice. The objective…
Abstract Number: 1848 • 2017 ACR/ARHP Annual Meeting
NMR-Based Serum Metabolomics of Patients with Takayasu Arteritis (TA) and Relationship with Disease Activity
Ramnath Misra¹, Avinash Jain², Dinesh Kumar³, Durga Prasanna Misra⁴, Anupam Guleria⁵, Sandeep Kumar⁴, Atul Rawat³, Smriti Chaurasia⁴, Umesh Kumar⁶, Abhishek Zanwar⁴, Durgesh Dubey⁷, Ruchika Goel⁸, Debashish Danda⁹ and Paul Bacon¹⁰, ¹Clinical Immunology, Sanjay Gandhi Postgraduate of Medical Sciences, Lucknow, India, ²Clinical Immunology, Senior Resident, Lucknow, India, ³Centre for Biomedical Research, Lucknow, India, ⁴Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁵Centre for Biomedical Research, DST-INSPIRE Faculty, Lucknow, India, ⁶Centre for Biomedical Research, Research Scholar, Lucknow, India, ⁷Centre for Biomedical Research, PhD Student, Lucknow, India, ⁸Rheumatology, Christian Medical College, Vellore Tamilnadu, India, ⁹Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹⁰Rheumatology, Emeritus Professor, Birmingham, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis of unknown pathogenesis. The current serological and radiological parameters used to assess disease activity are not…
Abstract Number: 2353 • 2017 ACR/ARHP Annual Meeting
The Relationship between Disease Activity, VEGF and E-Selectin Levels with Arterial Stiffness in Rheumatic Patients Treated with Biological Agents
Taskin Senturk¹, Huseyin Baygin¹, Gokhan Sargin¹, Hakan Akdam² and Mustafa Yilmaz³, ¹Rheumatology, Adnan Menderes University, Aydin, Turkey, ²Nephrology, Adnan Menderes University, Aydin, Turkey, ³Biochemistry, Adnan Menderes University, Aydin, Turkey
Background/Purpose: Rheumatic diseases are chronic-inflammatory disease associated with endothelial damage, changes in vascular permeability and plaque formation. VEGF and E-selectin play an important role in…
Abstract Number: 2582 • 2017 ACR/ARHP Annual Meeting
Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
Seong-Min Kweon¹, Seung-Geun Lee², Ji-Heh Park², Eun-Kyoung Park³, Yun-Kyung Kim⁴, Geun-Tae Kim⁵ and Dong Hyun Sohn⁶, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Busan, Korea, Republic of (South), ²Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, Republic of (South), ⁴Internal Medicine, Kosin University College of Medicine, Busan, South Korea, Busan, Korea, Republic of (South), ⁵Kosin University College of Medicine, Busan, Korea, Republic of (South), ⁶Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, Korea, Republic of (South)
Compliance and persistence with hydroxychloroquine in patients with systemic lupus erythematosusBackground/Purpose: Lifelong treatment with hydroxychloroquine (HCQ) is now recommended for all patients with systemic lupus…
Abstract Number: 2958 • 2017 ACR/ARHP Annual Meeting
Validation of Flare Criteria for Children and Adolescents with Systemic Lupus Erythematosus
Hermine I. Brunner¹, Michael J. Holland², Michael W. Beresford³, Nicolino Ruperto⁴, Stacy P. Ardoin⁵, Simone Appenzeller⁶, Clovis A Silva⁷, Glaucia V. Novak⁷, Daniela M. Lourenço⁸, Francisco Flores⁹, Beatrice Goilav¹⁰, Scott E. Wenderfer¹¹, Deborah M. Levy¹², Angelo Ravelli¹³, Raju Khubchandani¹⁴, Tadej Avcin¹⁵, Marisa S. Klein-Gitelman¹⁶, Brian M. Feldman¹⁷ and Jun Ying¹⁸, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³On Behalf of the UK JSLE Study Group, Liverpool, United Kingdom, ⁴Istituto Giannina Gaslini, Genoa, Italy, ⁵Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, ⁷Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁸Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁹Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ¹¹Pediatrics-Renal, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ¹²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹³University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹⁴Department of Paediatrics, Jaslok Hospital and Research Center, Mumbai, India, ¹⁵Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ¹⁶Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, ¹⁷Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is characterized by changing disease activity: episodes of improvement are often followed by episodes of worsening, i.e. flares. Considering…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].